Cleveland HeartLab to be acquired by Quest Diagnostics

October 19, 2017

Cleveland HeartLab has agreed to be acquired by Quest Diagnostics, a Fortune 500 medical testing company based in New Jersey. The deal should help the Cleveland Clinic spinout company accelerate its growth, said Cleveland HeartLab CEO Jake Orville. “We’re still a fraction of a fraction of what the real opportunity is,” Orville said, adding that he expects […]

Read More...

Putting precision care on the spot

October 8, 2017

The role of precision medicine in day-to-day clinical care is still limited, but Northeast Ohio could play a major part in bringing it to the mainstream. Proponents point to genomics as an area of personalized health that can revolutionize all aspects of the health care delivery system. Genomics is the study of genes in making […]

Read More...

Scout RFP raises $15.5 million to help companies manage purchases

June 7, 2017

Running a company is expensive. And it’s more than just the product and employee costs that add up. From furniture to electronics, there’s a lot of day-to-day corporate spending that can be hard to keep tabs on. That’s why procurement software has become a big business. Investors are betting that Scout RFP will emerge as […]

Read More...

When Supplier Sourcing Strategy Goes Beyond Cheaper Prices

May 24, 2017

By now it’s not news that procurement has gone through an evolution, one that is digital, automated and a potential area of strategy for the overall enterprise. But what may come as a surprise is that strategic sourcing has emerged as one of the most important parts of the procure-to-pay process, says Stan Garber, president […]

Read More...

Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position

May 4, 2017

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued:  U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242.  Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly […]

Read More...

Best of Tech Awards honors 7 companies during Tech Week

April 29, 2017

Tech Company of the Year Winner: Futuri Media About 200 people came out Thursday night to find out which seven companies would claim the top Best of Tech Awards at OHTec’s 11th annual event held at Trinity Cathedral in Cleveland. From startup companies that were recognized earlier in the week, to Avon High School winning a […]

Read More...

The University of Florida College of Journalism and Communications Creates R&D Lab With Futuri Media

April 25, 2017

The University of Florida College of Journalism and Communications (UFCJC) and media technology innovator Futuri Media Monday announced a unique partnership on an unprecedented research and development lab.   Read more…

Read More...

Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position

February 24, 2017

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, U.S. Patent No. 9,575,065.  Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including this newly issued patent.  Originally discovered and developed […]

Read More...

Futuri Media Unveils New Enhancements For POST Podcast Publishing System

February 9, 2017

FUTURI MEDIA‘s POST podcast publishing system has received some new enhancements, including a touchscreen interface, editing tool, and planning module. Read more: 

Read More...

Cleveland startup GenomOncology adds vice president of medical affairs

December 1, 2016

GenomOncology, a Cleveland company that has developed a technology platform to streamline the use of next-generation sequencing data in medical care and research, said it has named Dr. Joshua F. Coleman as vice president of medical affairs. Read More…

Read More...